Indoco Remedies share news, announcements and annual reports
NSE: INDOCOBSE: 532612Pharmaceuticals & BiotechnologySmall Cap
Indoco Remedies Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2005
Last close ₹208.30down ₹1.20 (0.57%)BSE ₹208.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹209.50.
30 Oct: open ₹208.65, high ₹210.00, low ₹205.10
52-week range of traded prices to 30 Oct 2026
₹162.19Low, 30 Mar 2026₹288.00High, 6 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,923 Cr1,173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 60.20
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.10%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.2%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −10.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.96
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 64,72755.0% delivered
Indoco Remedies share news and announcements
729 announcements, routine notices left out, newest first. Page 12 of 15.
May 2016
25 May · Analysts
Apr 2016
4 Apr · Analysts
Mar 2016
9 Mar · Corporate action
Jan 2016
Dec 2015
2 Dec · Updates
Oct 2015
Jul 2015
31 Jul · Disclosure of Voting Pattern - Clause 35A
30 Jul · Disclosure of Voting Pattern - Clause 35A
30 Jul · Results
Jun 2015
24 Jun · Meeting
May 2015
27 May · Meeting
Register of Members and Share Transfer Books of the Company shall remain closed from July 23, 2015 to July 30, 2015 (both days inclusive) for the purpose of Dividend and Annual General Meeting of the Company scheduled to be held on July 30, 2015.27 May · Dividend
Board of Directors at its meeting held on May 27, 2015 has approved payment of dividend of Rs. 1.60 per equity share on the face value of Rs. 2/- each i.e 80% for the financial year 2014-15 subject to approval of members. The dividend when approved at the AGM will be paid on or after August 05, 2015 to those shareholders whose names appear on the register of members as on the record date.18 May · Code of Conduct under SEBI(PIT) Reg., 2015
Apr 2015
Mar 2015
Jan 2015
30 Jan · Results
16 Jan · Board meeting
Inter-alia, for taking on record the un-audited financial results for the quarter ended December 31, 2014.
Oct 2014
9 Oct · Board meeting
Inter-alia, for taking on record the unaudited financial results for the second quarter ended September 30, 2014.Trading window of the Company shall remain closed w.e.f October 10, 2014 and shall end after 24 hours from the conclusion of the aforesaid Board Meeting.
Aug 2014
7 Aug · Management
Jul 2014
31 Jul · Disclosure of Voting Pattern - Clause 35A
21 Jul · Updates
Based on the inspection carried out by the USFDA in August 2013, the company has received Establishment Inspection Report (EIR) approving the company's sterile manufacturing facility (Plant II) and solid dosage manufacturing facility (Plant III) located in Verna, Goa.16 Jul · Board meeting
Inter-alia, for taking on record the unaudited financial results for the first quarter ended June 30, 2014
May 2014
28 May · Board meeting
Board of Directors in its meeting held on May 28, 2014 has approved appointment of Dr. Anand Nadkarni (DIN 06881461) as Additional Non Executive Director of the Company liable to retire by rotation w.e.f. May 28, 2014.
Mar 2014